Impact of coronary artery calcium score screening on cardiovascular risk stratification of patients with atrial fibrillation undergoing ablation

Data de publicação: Data Ahead of Print:

Autores da FMUP

  • Ricardo Manuel Alves Monteiro Fontes De Carvalho

    Autor

  • Ricardo José Araújo Ladeiras Lopes

    Autor

Participantes de fora da FMUP

  • Fernandes, S
  • Cruz, I
  • Faria, R
  • Almeida, J
  • Fonseca, P
  • Ferreira, N
  • Primo, JJ

Unidades de investigação

Abstract

Introduction: There is a well-established association between atrial fibrillation (AF) and coronary artery disease. Coronary artery calcium score (CACS) is a helpful tool to refine cardiovascular (CV) risk stratification and inform on the best strategies for primary CV prevention. This study aims to evaluate the impact of opportunistic screening with CACS on risk stratification and decision of preventive therapies, in patients with AF. Methods: Cross-sectional study including patients with AF or atrial flutter undergoing cardiac computed tomography for ablation procedure planning, from 2017 to 2019. Baseline clinical and demographical data were collected. CACS was assessed in patients without coronary artery disease using the Agatston method. Results: A total of 474 patients were included (93% with AF, mean age of 58 & PLUSMN; 10 years, 62% male). CACS >0 was present in 254 (54%) patients. According to CACS and the Society of Cardiovascular Computed Tomography recommendations, 25% of the patients would be candidates for statin therapy and 17% would be candidates for changes in the current statin intensity; in 11 patients (8%) acetylsalicylic acid would be recommended. Discussion/Conclusion: In our study, more than half of the patients undergoing cardiac computed tomography before AF catheter ablation had CACS above zero. Our findings suggest that an opportunistic evaluation of CACS at the time of ablation can be an important tool to improve CV risk stratification, with important clinical and therapeutic implications.

Dados da publicação

ISSN/ISSNe:
0008-6312, 1421-9751

Cardiology  S. Karger AG

Tipo:
Article
Páginas:
427-433
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 1

Citações Recebidas na Scopus: 3

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • PROGNOSTIC VALUE; DISEASE; PREVALENCE; ADULTS

Proyectos asociados

Dapagliflozin, Spironolactone or Both for HFpEF (SOGALDI-PEF) - NCT05676684

Investigador Principal: João Pedro Melo Marques Pinho Ferreira

Ensaio Clínico Académico (SOGALDI-PEF) . AstraZeneca . 2022

Screening of Fabry Disease in Portuguese Patients With Idiopathic Cardiomyopathies (F-CHECK) - NCT05409846

Investigador Principal: Elisabete Lousada Martins Oliveira Bernardes

Estudo Observacional Académico (F-CHECK) . Sanofi . 2022

The Impact of Obesity on Cardiac Function and Morphology in Aortic Stenosis

Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho

Estudo Clínico Académico (Obesity) . 2020

Suboptimal control of cardiovascular risk factors in myocardial infarction survivors

Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho

Estudo Clínico Académico (myocard) . 2020

Modeling Aortic Stenosis progression: impact on follow-up, treatment, and survival

Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho

Estudo Clínico Académico . 2022

Epicardial adipose tissue volume is not an independent predictor of atrial fibrillation recurrence after ablation

Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho

Estudo Clínico Académico . 2022

Social Media Use by Cardiovascular Healthcare Professionals in Portugal

Investigador Principal: Ricardo José Araújo Ladeiras Lopes

Estudo Clínico Académico (Cardiovascular Healthca) . 2022

Flow-status in severe aortic stenosis for percutaneous valve implantation: Should we follow the flow?

Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho

Estudo Clínico Académico . 2022

Cardiovascular Impact of Metabolic Syndrome: From Mechanisms to New Treatment Targets

Investigador Principal: Ricardo Manuel Alves Monteiro Fontes de Carvalho

Estudo Clínico Académico . 2021

Citar a publicação

Partilhar a publicação